The GDPR (General Data Protection Regulation) includes provisions that support the secondary use of existing health data for scientific research purposes, while also protecting the privacy and data protection rights of individuals.
One of the key ways that the GDPR supports the secondary use of health data for research is through the concept of “legitimate interests”. Article 6(1)(f) of the GDPR allows for the processing of personal data if it is necessary for the legitimate interests of the data controller or a third party, provided that those interests do not override the fundamental rights and freedoms of the data subject. Scientific research can be considered a legitimate interest, provided that appropriate safeguards are in place to protect individuals’ rights and freedoms.
In addition, the GDPR includes provisions that specifically address the use of health data for scientific research. For example, Article 9(2)(j) allows for the processing of special categories of personal data, such as health data, for scientific research purposes, provided that appropriate safeguards are in place.
The GDPR also requires that data controllers implement appropriate technical and organizational measures to ensure the security and confidentiality of personal data, including health data. This includes requirements for data pseudonymization and encryption, as well as procedures for data breach notification.
Overall, the GDPR strikes a balance between protecting individuals’ privacy and data protection rights, and supporting the important public interest in scientific research. By providing a framework for the responsible and transparent use of health data for research purposes, the GDPR can help to facilitate the development of new treatments and interventions that can improve public health outcomes.
Share this story...
Real World Evidence (RWE) 101 – Study Designs
RWE 101 - Study Designs Real-world evidence (RWE) studies are becoming increasingly important in healthcare decision-making. There are various study designs used to generate RWE, each with their unique [...]
Real World Evidence (RWE) 101 – Protocol Considerations
RWE 101 - Protocol Considerations Real-world evidence (RWE) study protocols and clinical trial protocols both outline the design and conduct of a study. However, they are distinctly different in [...]
Real World Evidence (RWE) 101 – PASS Approval Requirements
RWE 101 - PASS Approval Requirements Post-authorisation safety studies (PASS) are studies conducted after a medicine has been authorized (licensed) with the goal of acquiring more data about the [...]
Real World Evidence (RWE) 101 – Categories of PASS
RWE 101 - Categories of PASS Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a product derived from the analysis of [...]
Real World Evidence (RWE) 101 – Safety Monitoring
RWE 101 - Safety Monitoring Real World Evidence (RWE) complements clinical trials and provides additional insights that are difficult to achieve in controlled environments. Here's why:[1] Sample Size and [...]
Real World Evidence (RWE) 101 – How RWE is Being Used to Support the Treatment of Cancer
RWE 101 - How RWE is Being Used to Support the Treatment of Cancer Real-world evidence (RWE) enhances cancer treatment through providing more comprehensive and personalized patient data. Here [...]







